Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Dec 10, 2013
Issued Date -
N/A
app pub date -
Dec 28, 2012
filing date -
May 13, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention provides a class of substituted quinazolinone compounds and methods of treating diseases mediated by PI3Kδ activity. The disclosed compounds are useful in treating diseases such as bone-resorption disorders; and cancer, especially hematopoietic cancers, lymphomas, multiple myelomas and leukemia. The compounds are also useful in disrupting or inhibiting cellular processes such as leukocyte function or accumulation, neutrophils function, lymphocyte proliferation, and endogenous immune responses.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully